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Abstract 31	
L-lactate plays an important role as metabolite and signaling molecule in eukaryotes 32	
and bacteria. Monocarboxylate transporters (MCTs) of the SLC16 solute carrier family 33	
are responsible for the transport of L-lactate across eukaryotic and bacterial cell 34	
membranes. Here we report an efficient protocol for the expression and purification of 35	
an SLC16 family homologue in milligram amounts. The purified protein is stable and 36	
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Monocarboxylate transporters (MCTs) of the SLC16 solute carrier family 57	
(TCID 2.A.1.13), which comprises 14 members in the human genome, mediate 58	
stereoselective transport of L-lactate across plasma membranes [1]. MCTs 1-4 have 59	
been experimentally verified as proton-coupled L-lactate transporters [1]. MCT1 60	
(SLC16A1) is ubiquitously expressed, but its expression level is increased in L-lactate 61	
oxidizing cells (e.g., erythrocytes). MCT2 (SLC16A7) is found in the brain, kidney, 62	
liver, and in the testis, while the expression of MCT3 (SLC16A8) is restricted to the 63	
basal membrane of the retinal pigment and choroid plexus epithelia. MCT4 (SLC16A3) 64	
is localized in glycolytically active and anaerobic tissues and its expression is under the 65	
control of the hypoxia-inducible factor 1α [2]. While MCTs 1 and 2 are involved in L-66	
lactate uptake (MCT1: KM 3-5 mM, MCT2: KM ~0.7 mM), MCT4 (KM 20-35 mM) 67	
catalyzes the extrusion of accumulated L-lactate out of cells [1]. It has been shown that 68	
L-lactate plays an important role in cancer metabolism [3]. Due to metabolic disorder, 69	
certain cancer cells cannot cover their demand of energy by oxidative phosphorylation 70	
even under aerobic conditions. Therefore, they exhibit highly increased glycolysis rates 71	
resulting in the accumulation of L-lactate, which has to be shuttled out of the cell by 72	
overexpressed MCT4. In cancer tissue, the acidification of the tumor microenvironment 73	
resulting from co-transported protons is beneficial for tumor propagation and survival 74	
[4]. Furthermore, exported L-lactate serves as fuel for proliferating cancer cells that 75	
import L-lactate through overexpressed MCT1 [5]. Inhibiting the transport function of 76	
MCT1 and MCT4, which have complementary roles, has been proposed as a promising 77	
strategy for treating certain cancer types. This is reflected by clinical trials involving an 78	
MCT1 inhibitor (see AZD3965 at http://www.clinicaltrials.gov/) and a recent study that 79	
identified the antihypertensive drug syrosingopine as MCT4 inhibitor [6]. However, the 80	
design of potent and highly selective inhibitors as well as the possibility of reliable 81	
molecular docking has been hampered by the lack of experimental structures of the 82	
SLC16 family in the past. 83	
Using X-ray crystallography we have recently solved structures of a proton-84	
coupled L-lactate transporting SLC16 homologue from Syntrophobacter fumaroxidans 85	
(SfMCT) with bound substrate (i.e., L-lactate) and inhibitor (i.e., thiosalicylate) [7]. 86	
The structures, which represent the first structural information of the SLC16 family, 87	
show SfMCT in the pharmacologically relevant outward-open conformation where the 88	
binding site is accessible from the extracellular side. Here we report a detailed 89	
overexpression and purification procedure to obtain milligram amounts of highly pure, 90	
stable and detergent-solubilized SfMCT. The purified protein can be used for structure 91	
determination as well as for biochemical and biophysical characterization.  92	
 93	
Materials and Methods 94	
Cloning 95	
A major facilitator superfamily-type transporter from Syntrophobacter fumaroxidans 96	
(SfMCT, UniProt ID code A0LNN5) was identified as a bacterial homologue of human 97	
proton-dependent L-lactate transporting SLC16 members (i.e., MCT1, MCT2, MCT3, 98	
and MCT4) by searching the bacterial target database of the UniProt Knowledgebase 99	
on ExPASy using the BLAST algorithm (https://web.expasy.org/blast/). A codon-100	
optimized version of SfMCT was synthesized for expression in Escherichia coli 101	
(GenScript) containing 5’-HindIII and 3’-XhoI restriction sites, which were used to 102	
ligate the gene into the pZUDF21-rbs-3C10His plasmid [8] for protein overexpression. 103	
For ligation of the SfMCT gene into the pEXT20 plasmid [9], which was used for 104	
bacterial uptake assays, the 5’-HindIII was replaced by a 5’-EcoRI restriction site using 105	
polymerase chain reaction whereas the 3’-XhoI restriction site was kept. The resulting 106	
constructs (pZUDF21-rbs-SfMCT-3C10His and pEXT20-SfMCT-3C10His) contained 107	
a C-terminal human rhinovirus 3C (HRV 3C) protease cleavage site and a 108	
decahistidine-tag (His-tag) for affinity purification.  109	
Bacterial uptake assay 110	
For the bacterial uptake assay, E. coli JA202 (MC4100 glcA::cat lldP::kan) [10], which 111	
lacks the endogenous L-lactate transporters LldP and GlcA, was transformed with the 112	
empty plasmid (pEXT20-3C10His) or the plasmid encoding SfMCT (pEXT20-113	
SfMCT-3C10His). The transformed strains were inoculated in 25 ml Luria Bertani (LB) 114	
Broth (VWR Life Science) supplemented with 100 µg/ml ampicillin and 50 µg/ml 115	
kanamycin, and grown overnight at 37°C and 180 rpm in an incubator shaker 116	
(Multitron, Infors HT). The overnight cultures were diluted 1:200 into LB Broth 117	
supplemented with 100 µg/ml ampicillin, and grown at 37ºC and 180 rpm in an 118	
incubator shaker. Protein expression was induced at OD600 ~0.5 by addition of 119	
isopropyl-β-D-thiogalactopyranoside (IPTG, Apollo Scientific) to a final concentration 120	
of 250 µM. After 4 h, bacteria were pelleted (5,200 x g, 10 min, room temperature) and 121	
resuspended in uptake buffer (20 mM Bis-Tris propane-HCl (pH 6.7), 250 mM KCl) to 122	
a bacteria density of OD600 12. The assay volume of the uptake experiments was 50 µl, 123	
which included 20 µl of cell suspension (2.4×108 bacteria) and 30 µl of radiolabel 124	
master mix (22 µM sodium L-lactate spiked with [14C(U)] L-lactic acid sodium salt 125	
([14C]L-lactate, American Radiolabeled Chemicals) to a specific activity of 0.15 126	
Ci/mmol). The uptake experiments were performed in 2 ml reaction tubes (Eppendorf) 127	
at 30ºC under agitation (1,000 rpm, Thermomixer compact, Eppendorf). 900 µl of stop 128	
buffer (20 mM HEPES-NaOH (pH 7.5), 150 mM NaCl) were added at different time 129	
points (5-120 min) to terminate the uptake of L-lactate. Bacteria were immediately 130	
pelleted by centrifugation (21,000 x g, 4 min, room temperature) and washed twice with 131	
900 µl stop buffer by repeating the previous centrifugation step. 50 µl of a 5% (w/v) 132	
sodium dodecylsulfate (SDS) solution were added to lyse the bacteria overnight and to 133	
release the transported [14C]L-lactate. Lysed bacteria were transferred into a white 96-134	
well plate (OptiPlate, PerkinElmer) and 150 µl of scintillation cocktail (MicroScint 40, 135	
PerkinElmer) were added before measuring each reaction for 2 min with a scintillation 136	
counter (TopCount NXT, PerkinElmer). 137	
Test expression of SfMCT in different E. coli strains and Western blot analysis 138	
Different chemically competent E. coli strains (i.e., BL21(DE3), BL21(DE3) pLysS, 139	
BL21(DE3) Gold, BL21(DE3) RIPL, Rosetta(DE3), Rosetta2(DE3), Rosetta2(DE3) 140	
pLysS, C41(DE3), C43(DE3)) were transformed with pZUDF21-rbs-SfMCT-3C10His 141	
using heat shock (60 s at 42°C), followed by growth in 900 µl LB Broth for 1 h at 37°C 142	
under agitation (800 rpm, Thermomixer compact, Eppendorf). 25 ml of LB Broth 143	
supplemented with 100 µg/ml ampicillin and 36 µg/ml chloramphenicol (for strains 144	
BL21(DE3) pLysS, Rosetta(DE3), Rosetta2(DE3) and Rosetta2(DE3) pLysS) were 145	
inoculated with the transformed E. coli strains and grown overnight at 37°C in an 146	
incubator shaker (180 rpm, Multitron, Infors HT). The overnight cultures were diluted 147	
1:200 in 50 ml LB Broth supplemented with 100 µg/ml ampicillin and grown at 37°C 148	
in an incubator shaker (180 rpm, Multitron, Infors HT) to an OD600 of ~0.9. At this 149	
point, IPTG was added to a final concentration of 250 µM to induce SfMCT expression. 150	
After four hours, 2 ml of expression culture were pelleted in 2 ml reaction tubes (21,000 151	
x g, 10 min, room temperature), the supernatant was removed, and the pellet was stored 152	
at -20°C. For Western blot analysis the bacteria pellets were thawed and incubated with 153	
600 µl of non-reducing sample buffer (60 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 154	
2% (w/v) SDS, 0.01% (w/v) bromophenol blue) for 30 min at 24°C under agitation 155	
(800 rpm, Thermomixer compact, Eppendorf). The samples were then diluted twofold 156	
in non-reducing sample buffer and separated on a 14% SDS-PAGE gel. Subsequently, 157	
proteins were transferred to a methanol-activated polyvinylidene difluoride membrane 158	
(PVDF, Immobilon-P Transfer Membrane, Merck Millipore) using a semi-dry blotting 159	
system (Trans-blot SD Semi-Dry Transfer Cell, Bio-Rad) operated at 22 V for 25 min 160	
at room temperature. The transfer buffer (48 mM Tris, 39 mM glycine, 1.3 mM SDS, 161	
20% (v/v) methanol) was freshly prepared. After the transfer, the PVDF membrane was 162	
rinsed with Tris-buffered saline (TBS; 10 mM Tris-HCl (pH 8), 150 mM NaCl) and 163	
incubated in 30 ml blocking solution (3% bovine serum albumin (BSA) in TBS) on an 164	
orbital shaker for 1 h at room temperature. After removing the blocking solution, the 165	
membrane was directly incubated with a mouse anti-His5 primary antibody (Qiagen, 166	
catalogue number 34660) at a dilution of 1:3,000 in 30 ml blocking solution on an 167	
orbital shaker for 1 h at room temperature. After washing the PVDF membrane three 168	
times for 10 min with 30 ml TBS, it was incubated with a secondary goat anti-mouse 169	
IgG (H+L) HRP conjugate antibody (Bio-Rad, catalogue number 172-1011) at a 170	
dilution of 1:2,500 in 30 ml 5% (w/v) non-fat dry milk powder (Rapilait, Migros) in 171	
TBS on an orbital shaker for 1 h at room temperature. Finally, the PVDF membrane 172	
was washed four times for 10 min with 30 ml Tween-20-supplemented TBS (10 mM 173	
Tris-HCl (pH 8), 150 mM NaCl, 0.05% (v/v) Tween-20) followed by incubation in 6 174	
ml electrochemiluminescence solution (Amersham ECL Western blotting Detection 175	
Reagents, GE Healthcare) for 2 min. Antibody-labelled proteins were detected by 176	
exposing X-ray films (Fujifilm) for 5 seconds. 177	
Large-scale expression and membrane isolation 178	
Based on test expressions using various E. coli strains (see Test expression section), 179	
E. coli BL21(DE3) pLysS was selected as expression host for large-scale expression of 180	
SfMCT in an incubator shaker (Multitron, Infors HT). LB Broth supplemented with 181	
100 µg/ml ampicillin and 36 µg/ml chloramphenicol was inoculated with transformed 182	
E. coli BL21(DE3) pLysS from a glycerol stock prepared from the test expression 183	
cultures and grown overnight at 37°C in an incubator shaker (180 rpm, Multitron, Infors 184	
HT). A typical SfMCT overexpression batch contained 30 l of LB Broth split into 185	
fifteen 5 l plain bottom Erlenmeyer flasks. The overnight culture was diluted 1:200 in 186	
2 l LB Broth supplemented with 100 µg/ml ampicillin and grown at 37°C in an 187	
incubator shaker (180 rpm, Multitron, Infors HT) to an OD600 of ~0.9. At this point, 188	
250 µM IPTG were added to induce SfMCT expression. After four hours, bacteria were 189	
harvested by centrifugation (10,000 x g, 6 min, 4°C). The resulting pellet was 190	
resuspended in ice-cold lysis buffer (45 mM Tris-HCl (pH 8), 450 mM NaCl) and 191	
pelleted again (10,000 x g, 25 min, 4°C). The final bacteria pellet was resuspended in 192	
lysis buffer and stored at -20°C until further use. For isolating the membranes, bacteria 193	
were thawed at room temperature and disrupted using a pre-cooled M-110P 194	
Microfluidizer (Microfluidics) operated at 1,500 bar during six passages. Unlysed 195	
bacteria were removed by low-speed centrifugation (10,000 x g, 10 min, 4°C) and the 196	
supernatant was then subjected to ultracentrifugation (200,000 x g, 90 min, 4°C). The 197	
resulting pellet was resuspended in lysis buffer, homogenized using a glass teflon 198	
homogenizer (Sartorius) and again subjected to ultracentrifugation (200,000 x g, 90 199	
min, 4°C). Membranes were finally resuspended and homogenized in solubilization 200	
buffer (20 mM Tris-HCl (pH 8), 150 mM NaCl, 10% (v/v) glycerol) using a glass teflon 201	
homogenizer. Isolated and washed membranes were finally diluted to 100 mg/ml and 202	
stored at -80°C. Typically 0.25-0.5 g of membranes (i.e., wet weight) were obtained 203	
from 1 l of expression culture. 204	
 205	
Purification of SfMCT 206	
Purification of SfMCT was performed at 4°C unless otherwise stated. Isolated and 207	
washed membranes were thawed at room temperature and solubilized in solubilization 208	
buffer (25 ml for membranes from 2 l of expression culture) containing 2% (w/v) n-209	
dodecyl-β-D-maltopyranoside (DDM, Glycon Biochemicals) by gentle agitation on a 210	
magnetic stirrer for 2 h. Unsolubilized and aggregated material was removed by 211	
ultracentrifugation (200,000 x g, 30 min, 4°C). The supernatant was diluted twofold 212	
with detergent-free washing buffer (20 mM Tris-HCl (pH 8), 150 mM NaCl, 5 mM L-213	
histidine, 5% (v/v) glycerol) and incubated with nickel-nitrilotriacetate resin (Ni-NTA; 214	
ProteinIso; 1 ml resin bed volume for solubilized membranes from 1 l of expression 215	
culture) for 2 h under gentle stirring. The Ni-NTA resin was then transferred into a 216	
glass chromatography column (Econo-Column, Bio-Rad) using a peristaltic pump 217	
(Peristaltic Pump P-1, Pharmacia Fine Chemicals) operated at a flow rate of 4 ml/min. 218	
The resin was washed with 25 column volumes of washing buffer (20 mM Tris-HCl 219	
(pH 8), 150 mM NaCl, 5 mM L-histidine, 5% (v/v) glycerol, 0.03% (w/v) DDM) and 220	
with 25 column volumes of size-exclusion chromatography (SEC) buffer (20 mM Tris-221	
HCl (pH 8), 150 mM NaCl, 0.03% (w/v) DDM) at a flow rate of 0.8 ml/min. 400 µl of 222	
SEC buffer and 500 µg of His-tagged HRV 3C protease (BioVision, Milpitas, CA, 223	
USA; stored in 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 50% (v/v) glycerol, 5 mM 224	
β-mercaptoethanol) per 1 ml of column bed volume were added to the Ni-NTA in order 225	
to elute SfMCT during overnight on-column cleavage on a rotational shaker. SfMCT 226	
and unbound His-tagged HRV 3C protease were spin-eluted from the column (3,000 x 227	
g, 3 min, 4°C) followed by reverse Ni-NTA purification to remove uncleaved SfMCT 228	
and co-eluted His-tagged HRV 3C protease. For that purpose, the elution volume was 229	
incubated with 150 µl bed volume Ni-NTA per mg of His-tagged HRV 3C protease for 230	
10 min on a rotational shaker. The Ni-NTA resin was removed by passing the mixture 231	
over a disposable column (Wizard Midicolumns, Promega). Finally, aggregated 232	
proteins were removed by ultracentrifugation (150’000 x g, 20 min, 4°C).  233	
Size-exclusion chromatography 234	
Size-exclusion chromatography (SEC) was performed using a Superdex 200 10/300 235	
GL column (GE Healthcare) that was connected to a fast protein liquid chromatography 236	
(FPLC) system (Äkta Purifier, GE Healthcare) operated at a flow rate of 0.5 ml/min. 237	
The column was equilibrated with 1.5 column volumes of SEC buffer (20 mM Tris-238	
HCl (pH 8), 150 mM NaCl, 0.03% (w/v) DDM) before injecting 50 µg (100 µl, 0.5 239	
mg/ml) of purified, DDM-solubilized SfMCT. The SfMCT elution profile was detected 240	
at an absorption wavelength of 280 nm and processed using the UNICORN software 241	
(GE Healthcare). 242	
Gel electrophoresis 243	
Denaturing SDS-PAGE was performed using a 14% SDS-PAGE gel where 20 µg of 244	
purified, DDM-solubilized SfMCT were loaded. The gel was stained with Coomassie 245	
Brilliant blue R-250 (AppliChem) to visualize the protein bands. Precision Plus Protein 246	
unstained standard (Bio-Rad) was used as a molecular weight marker. For Blue Native 247	
(BN)-PAGE, 20 µl of a 0.25 mg/ml SfMCT sample (i.e., a total of 5 µg) were mixed 248	
with BN-PAGE loading buffer (final concentration 50 mM BisTris-HCl (pH 7.2), 50 249	
mM NaCl, 10% (w/v) glycerol) supplemented with 0.1% (w/v) DDM and 0.08% (w/v) 250	
Coomassie Brilliant blue G-250 (AppliChem). The SfMCT sample was loaded on a 4-251	
16% BisTris NativePAGE gel (ThermoFisher).	The gel was run using anode buffer (50 252	
mM BisTris (pH 6.8), 50 mM Tricine (pH 6.8)) and dark blue cathode buffer (50 mM 253	
BisTris (pH 6.8), 50 mM Tricine (pH 6.8), 0.02% (w/v) Coomassie Brilliant blue G-254	
250) at 150 V for the first 30 min and light blue cathode buffer (50 mM BisTris (pH 255	
6.8), 50 mM Tricine (pH 6.8), 0.002% (w/v) Coomassie Brilliant blue G-250) for the 256	
following 80 min at 250 V. The gel tank was suspended in ice water during the whole 257	
run. Thyroglobulin (669 kDa), ferritin (440 kDa), lactate dehydrogenase (140 kDa), and 258	
bovine serum albumin (66 kDa) were used as molecular weight markers. 259	
Determination of the thermostability of SfMCT 260	
The thermostability of SfMCT was determined as previously described using a 261	
combination of heat denaturation and SEC analysis [11,12]. Purified, DDM-solubilized 262	
SfMCT was diluted to 0.5 mg/ml (~11 µM) using SEC buffer (20 mM Tris-HCl (pH 263	
8), 150 mM NaCl, 0.03% (w/v) DDM). Aliquots of 150 µl were incubated in 200 µl 264	
reaction tubes (Sarstedt) for 2 min at 4°C and 10 min at different temperatures (4-60°C) 265	
in a thermocycler (SensoQuest GmbH). Heat-treated samples were centrifuged (18,000 266	
x g, 1 min, room temperature) to remove aggregates. 100 µl (i.e., 50 µg, 1.1 nmol) of 267	
SfMCT were loaded on a Tricorn 5/150 column (GE Healthcare) packed with Superdex 268	
200 PG resin (GE Healthcare), which was connected to an FPLC system (Äkta Purifier, 269	
GE Healthcare) and which was equilibrated with two column volumes of SEC buffer. 270	
SfMCT was eluted using SEC buffer at a flow rate of 0.55 ml/min and the elution 271	
profiles were detected at an absorption wavelength of 280 nm and processed using the 272	
UNICORN software (GE Healthcare). The maximum of the elution peak was plotted 273	
versus the incubation temperature to assemble a melting curve (i.e., absorption vs. 274	
temperature). Three independent melting curves, each consisting of triplicate data 275	
points, were normalized by fitting a sigmoidal model curve to each melting curve. 276	
Absorption values were normalized with respect to the determined upper plateau value, 277	
i.e., the fitted upper plateau value corresponds to 100%. The arithmetic average of three 278	
independent, normalized experiments was calculated. The melting temperature (Tm) of 279	
purified, DDM-solubilized SfMCT was determined by fitting a sigmoidal curve to the 280	
averaged, normalized melting curve using Prism6 (GraphPad Software) and using the 281	
temperature at which the normalized absorption dropped to 50% as Tm. 282	
Crystallization 283	
SfMCT was purified as described in the Purification of SfMCT section with the 284	
exception that DDM was replaced by n-nonyl-β-D-glucopyranoside (NG, Glycon 285	
Biochemicals). For solubilization, 4% (w/v) and for all purification steps 0.4% (w/v) 286	
NG were used. Purified, NG-solubilized SfMCT was concentrated to 8 mg/ml using a 287	
50,000 Da molecular weight cut-off ultrafiltration device (Vivaspin 2, SARTORIUS 288	
Stedim Biotech). The ultrafiltration device was centrifuged at 1,000 x g in 20 min 289	
intervals followed by resuspending the concentrate to avoid detergent gradient 290	
formation. Aggregated protein was removed by ultracentrifugation (150,000 x g, 30 291	
min, 4 ºC). The final glycerol concentration (see Purification of SfMCT section) was 292	
adjusted to 2.9% (v/v) and the sample was incubated on ice for 1 h prior to 293	
crystallization. A Mosquito Crystal Robot (TTP Labtech) was used to mix concentrated 294	
SfMCT with reservoir solution (50 mM HEPES-NaOH (pH 7), 5 mM ZnBr2, 30% (v/v) 295	
Jeffamine ED-2003). Crystallization trials were performed using the sitting-drop vapor-296	
diffusion method in 96-well 3-drop polystyrene crystallization plates (SWISSCI) 297	
covered by transparent foils (AMPLIseal, Greiner Bio-One). After one day of 298	
incubation at 18 ºC small crystals appeared, which reached maximal size after one 299	






Results and discussion 306	
Functional characterization of SfMCT 307	
SfMCT was identified as a bacterial homologue of the human proton-dependent L-308	
lactate transporting SLC16 members (i.e., MCTs 1-4). It shares 25 and 27% amino acid 309	
sequence identity, and 51 and 57% sequence similarity with human MCT1 and MCT4 310	
[7]. SfMCT was cloned into the pEXT20 expression plasmid and expressed in E. coli 311	
JA202 [10] to verify that it mediates the transport of L-lactate. A significantly higher 312	
uptake of [14C]L-lactate into SfMCT-overexpressing bacteria was measured over time 313	
compared with the uptake into bacteria that were transformed with an empty control 314	
plasmid (Fig. 1). The net uptake signal of SfMCT, which was calculated by subtracting 315	
the uptake into control plasmid-carrying bacteria from the uptake into SfMCT-316	
overexpressing bacteria, clearly shows that SfMCT transports L-lactate. Using the E. 317	
coli JA202 strain, which lacks the endogenous transporters LldP and GlcA, was 318	





Figure 1: Time-dependent uptake of [14C]L-lactate (13 µM) into SfMCT-expressing 324	
and plasmid transformed E. coli JA202 cells. The net uptake signal of SfMCT (red 325	
squares) was calculated by subtracting the uptake into control plasmid-carrying bacteria 326	
(black triangles) from the uptake into SfMCT-overexpressing bacteria (black circles), 327	
Data are represented as mean ± SEM from a representative triplicate experiment. 328	
 329	
Test-expression of SfMCT  330	
Expression of SfMCT was tested in different E. coli strains to identify a suitable 331	
expression host for large-scale expression. In these strains, which contain the l DE3 332	
lysogen that carries the gene for the T7 RNA polymerase, heterologous expression of 333	
SfMCT can be induced by IPTG and they have been successfully used for the 334	
overproduction of membrane proteins in the past [13]. Almost no expression was 335	
detected in E. coli BL21(DE3) and E. coli Rosetta(DE3) (Fig. 2, lanes 1 and 5). 336	
Interestingly, the expression was significantly higher in E. coli BL21(DE3) pLysS (Fig. 337	
2, lane 2), which carries the pLysS plasmid encoding the T7 lysozyme that prevents 338	
leaky expression in the absence of the inducer IPTG. A similar increase in expression 339	
in the presence of the pLysS plasmid was observed in E. coli Rosetta2(DE3) pLysS that 340	
showed the highest expression level among all tested strains as judged by Western 341	
blotting (Fig. 2, lanes 6 and 7). However, the high expression level in E. coli 342	
Rosetta2(DE3) pLysS was accompanied by high molecular weight aggregates that 343	
became visible as smears on the Western blot. Thus, this strain might not be optimal 344	
for obtaining stable and homogenous SfMCT as required for crystallization despite its 345	
high protein production capacity. A band at a molecular weight of ~70 kDa indicates 346	
SfMCT dimers whereas no low molecular weight bands were detected that would have 347	
indicated proteolytic degradation during protein expression. Finally, E. coli 348	
BL21(DE3) pLysS was selected as the preferred strain for overexpression of SfMCT 349	
because of the expected expression level and because this strain has been successfully 350	




Figure 2: Western blot of SfMCT expressed in different E. coli strains. Equal volumes 355	
of overexpression cultures were loaded on a 14% SDS-PAGE gel and detected using a 356	
mouse anti-His5 and a goat anti-mouse IgG (H+L) HRP conjugate antibodies. 1 357	
BL21(DE3), 2 BL21(DE3) pLysS, 3 BL21(DE3) Gold, 4 BL21(DE3) RIPL, 5 358	
Rosetta(DE3), 6 Rosetta2(DE3), 7 Rosetta2(DE3) pLysS, 8 C41(DE3), 9 C43(DE3). 359	
 360	
Purification and characterization of SfMCT 361	
We have established an efficient protocol for the purification of SfMCT that can be 362	
used for its biochemical characterization and crystallization. The cytosolic fraction was 363	
separated from SfMCT-containing membranes after bacteria lysis in order to reduce the 364	
amount of unspecific binding to the Ni-NTA resin. Isolated membranes were washed 365	
with a high-salt buffer (e.g., 45 mM Tris-HCl (pH 8), 450 mM NaCl) to reduce the 366	
amount of soluble and membrane-associated contaminants that might compete with 367	
His-tagged SfMCT for binding to the Ni-NTA resin [14]. According to our expression 368	
and membrane preparation protocol 0.25-0.5 g of washed bacterial membranes (i.e., 369	
wet weight) were obtained from 1 l of expression culture (Table 1). Efficient 370	
solubilization was achieved when membranes from 2 l expression culture were 371	
solubilized in a volume of 25 ml solubilization buffer using 2% (w/v) DDM. Elution of 372	
SfMCT by HRV 3C on-column proteolytic cleavage yielded pure protein as judged by 373	
Coomassie-stained SDS-PAGE (Fig. 3a) where SfMCT migrated at a molecular weight 374	
of ~30 kDa, which is lower than the amino acid sequence-based molecular weight of 375	
~45 kDa. Such discrepancies have been previously reported and are commonly 376	
observed for membrane proteins [15-18]. A second and weaker band at ~70 kDa was 377	
present, which was also observed on Western blots of bacteria expressing SfMCT (Fig. 378	
2). Therefore, this band represents an SfMCT population and it does not originate from 379	
a co-purified contaminant. The yield of the presented SfMCT purification procedure is 380	
1.5-2 mg of SfMCT per liter of expression culture (Table 1).  381	
The observed SfMCT population at ~70 kDa, which approximately corresponds 382	
to twice the mass of the main population, might lead to the speculation that SfMCT 383	
forms a dimer when expressed in E. coli and purified in DDM. This oligomeric state 384	
might then be disrupted by the denaturing environment of SDS-PAGE. To address this 385	
issue, DDM-purified SfMCT was analyzed by BN-PAGE where the oligomeric state 386	
of membrane proteins is maintained during gel electrophoresis [16]. SfMCT migrated 387	
as a single band at 85-95 kDa (Fig. 3b), which is the typical mass of a DDM-solubilized, 388	
monomeric membrane transporter observed in BN-PAGE [15,17]. Furthermore, SEC 389	
was performed to further assess the oligomeric state of DDM-solubilized SfMCT and 390	
to verify the homogeneity of the sample. The chromatogram of SfMCT contains a 391	
single peak at an elution volume of 12.7 ml indicating that the presented purification 392	
procedure yielded a monodisperse membrane protein sample (Fig. 3c). The elution 393	
volume is similar to the peak position of the monomeric, DDM-purified major 394	
facilitator superfamily transporter LacY, which has a similar molecular weight 395	
(SfMCT: ~45 kDa, LacY: ~48 kDa) [8]. Dimeric, DDM-purified membrane proteins of 396	
similar monomer weight elute at significantly lower volumes [8]. In summary, we have 397	
shown by BN-PAGE and SEC that SfMCT is a monomer when expressed in E. coli and 398	
purified in DDM. The species that migrates at a molecular weight of ~70 kDa reflects 399	
most probably to unspecific and SDS-PAGE induced aggregation of SfMCT. 400	
Thermostability of a purified, detergent-solubilized membrane protein can be a 401	
critical parameter for crystallization since it is generally exposed to temperatures higher 402	
than 4°C during crystal growth. The thermostability of SfMCT was determined using a 403	
previously described approach involving a combination of heat denaturation and SEC 404	
analysis [11,12]. An apparent melting temperature (Tm) of 46°C (95% confidence 405	
interval: 45.9 – 46.1°C) was measured for DDM-solubilized SfMCT (Fig. 3d), which 406	




Figure 3: Biochemical and biophysical characterization of DDM-purified SfMCT. (a) 411	
Coomassie-stained 14% SDS-PAGE gel of purified SfMCT (20 µg of protein loaded). 412	
Denatured SfMCT runs as a prominent band at ~30 kDa and as a minor second band at 413	
~70 kDa. (b) 4-16% BisTris NativePAGE linear gradient gel of purified SfMCT (5 µg 414	
of protein loaded). DDM-solubilized SfMCT migrates at 85-95 kDa. (c) SEC elution 415	
profile of purified SfMCT (50 µg) in SEC buffer. A monodisperse elution peak was 416	
detected at 12.7 ml. Void volume and retention volumes are indicated for the following 417	
standard proteins: thyroglobulin (TG, 669 kDa), ferritin (F, 440 kDa), aldolase (A, 158 418	
kDa), conalbumin (CA, 75 kDa), and ovalbumin (OA, 43 kDa). (d) Melting curve of 419	
SfMCT. The solid line represents the fitted sigmoidal curve that was used to determine 420	
the melting temperature (Tm). 95% confidence interval values are indicated below the 421	
Tm values. Data are represented as mean ± SD from triplicates.  422	
 423	
Table 1 SfMCT overexpression and purification table. Yield obtained from one 424	
liter of expression culture are indicated. 425	
Purification step Yield 
Bacteria pellet 1.5-2 g  
Membrane isolation 0.25-0.5 g  
HRV 3C elution in DDM 1.5-2 mg  
HRV 3C elution in NG 0.8-1 mg  
 426	
Crystallization of SfMCT 427	
Although pure, homogenous and thermostable SfMCT was obtained when purified in 428	
DDM, no crystals appeared in any crystallization screens. Therefore, SfMCT was also 429	
solubilized and purified in other uncharged maltoside-based (i.e., n-undecyl-β-D-430	
maltopyranoside UDM, n-decyl-β-D-maltopyranoside DM, n-nonyl-β-D-431	
maltopyranoside NM, n-octyl-β-D-maltopyranoside OM, 7-cyclohexyl-1-heptyl-β-D-432	
maltopyranoside Cymal-7, 6-cyclohexyl-1-hexyl-β-D-maltopyranoside Cymal-6, 5-433	
cyclohexyl-1-pentyl-β-D-maltopyranoside Cymal-5) and glucoside-based (n-nonyl-β-434	
D-glucopyranoside NG, n-octyl-β-D-glucopyranoside OG) detergents at 435	
concentrations shown in Table 2 and crystallization trials were performed. Trapezoid-436	
shaped crystals, which were suitable for collecting high-quality X-ray diffraction data 437	
[7], only grew when SfMCT was solubilized and purified in n-nonyl-β-D-438	
glucopyranoside (NG) (Fig. 4a). Different commercial screens were used for initial 439	
crystallization trials. Small crystals (<20 µm) grew in only one condition of the 440	
commercial MemGold screen (80 mM HEPES-NaOH (pH 7), 2 mM ZnSO4, 25% (v/v) 441	
Jeffamine ED-2001). This initial hit condition had to be optimized to obtain larger 442	
crystals (50 mM HEPES-NaOH (pH 7), 5 mM ZnBr2, 30% (v/v) Jeffamine ED-2003). 443	
The presence of Zn2+ cations was essential for crystal growth. In contrast to DDM, NG 444	
has a delipidating effect on ternary complexes (i.e., membrane protein, lipid, and 445	
detergent) and forms significantly smaller micelles [8]. This might be beneficial for 446	
promoting interactions between NG-solubilized SfMCT leading to well-ordered 447	
crystals as observed for other NG-solubilized members of the major facilitator 448	
superfamily [20,21]. Crystals grew on the bottom surface of the polystyrene 449	
crystallization plates and had to be gently detached by touching the crystals at the long 450	
side of the trapezoid with a cryo-loop.  451	
The quality of the obtained crystals made it possible to determine the first 452	
crystal structure of an SLC16 family member at 2.54 Å resolution [7]. SfMCT contains 453	
12 TMs and adopts the typical major facilitator superfamily fold [22,23], where TMs 454	
1-6 and TMs 7-12 form an N- and C-terminal six-helix bundle, which are related to 455	
each other by a pseudo-twofold symmetry axis (Fig. 4b, grey dashed line). The structure 456	
shows SfMCT in an outward-open conformation with a central, conical cavity that is 457	
open to the periplasmic side (Fig. 4b, star). The obtained crystals belonged to the space 458	
group P21212 with unit cell parameters of a = 106.77 Å, b = 200.54 Å, c = 64.56 Å and 459	
a = b = g = 90°. The asymmetric unit (Fig. 4c, dashed box) contained two SfMCT 460	
molecules and had a Matthews coefficient of 3.92 Å3/Da, which corresponds to a 461	
solvent content of ~69% [24]. Such a high solvent content is often observed for 462	
membrane protein crystals, and is attributed to the presence of ternary complexes 463	
consisting of membrane proteins, detergents and lipids [25]. This can reduce protein-464	
protein interactions and results in fragile membrane protein crystals. The two SfMCT 465	
molecules are tilted with respect to each other and make a crystal contact over TM12 466	
(Fig. 4c, triangle). Extracellular loops connecting TM7 and TM8 of two SfMCT 467	
monomers of adjacent asymmetric units form a second crystal contact (Fig. 4c, blue 468	
arrow), while a third crystal contact exists between the loop enclosed by TM6 and TM7, 469	
and the N-terminal end of TM10 (Fig. 4c, black arrow). The C-terminus of one SfMCT 470	
molecule is located in the periplasmic cavity of an SfMCT molecule located of a 471	
neighboring asymmetric unit thereby forming a fourth crystal contact (Fig. 4c, dashed 472	
circle). This contact highlights the importance of proteolytic His-tag removal since this 473	
affinity-tag would impede this crystal contact, which is highlighted by the fact that only 474	
HRV 3C cleaved protein resulted in crystal growth.  475	
Conclusion 476	
We have provided a protocol for the efficient overexpression and purification of the L-477	
lactate transporting SLC16 homologue SfMCT. Following this protocol pure, 478	
homogenous and thermostable protein can be obtained at quantities that allow 479	




Figure 4: Crystallization of NG-solubilized SfMCT. (a) The micrograph shows typical 484	
trapezoid-shaped crystals of SfMCT. (b) Overall structure of SfMCT in the outward-485	
open conformation. The central, conical cavity is highlighted by the asterisk and the 486	
grey, vertical broken line indicates the pseudo-twofold symmetry axis. N- and C-487	
termini are labeled. Parts of the loops connecting TM1 and TM2, TM5 and TM6 as 488	
well as TM6 and TM7 could not be fully traced and are therefore represented by broken 489	
lines. The model of SfMCT is colored based on rainbow coloring scheme from blue 490	
(N-terminus) to red (C-terminus). (c) Crystal packing and contacts of SfMCT in space 491	
group P21212. An asymmetric unit is highlighted by the dashed box. Crystal contacts 492	
are indicated by arrows, a triangle and a dashed circle.  493	
 494	
Table 2 Detergent concentrations used for solubilization and purification of 495	
SfMCT. All values are taken from https://www.anatrace.com/. The critical micelle 496	
concentration is abbreviated by CMC. 497	
Detergent Molecular 
weight 
CMC Solubilization  Purification 





DDM 510.6 0.0087 0.17 2 39.17 0.03 0.59 
UDM 496.9 0.029 0.59 2 40.25 0.1 2.01 
DM 482.6 0.087 1.8 2 41.44 0.3 6.22 
NM 468.5 0.28 6 4 85.38 0.4 13.05 
OM 454.4 0.89 19.5 4 88.03 1.5 33.01 
Cymal-7 522.5 0.0099 0.19 2 38.28 0.05 0.96 
Cymal-6 508.5 0.028 0.56 2 39.33 0.1 1.97 
Cymal-5 494.5 0.12-0.25 2.4-5.0 3 60.67 0.4 8.09 
NG 306.4 0.2 6.5 4 130.55 0.4 13.05 
OG 292.4 0.53-0.58 18-20 4 136.80 1 34.20 
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